Carotid Artery Disease Clinical Trial
— ROADSTEROfficial title:
INVESTIGATION of FLOW ALTERED, SHORT TRANSCERVICAL CAROTID ARTERY STENTING in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE With Filter.
Verified date | December 2016 |
Source | Silk Road Medical |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to evaluate the safety and effectiveness of the MICHI™ Neuroprotection System with Filter (MICHI™ NPS+f) in providing cerebral embolic protection during carotid artery stenting. It will be used in conjunction with a FDA approved carotid artery stent for the treatment of carotid artery disease.
Status | Completed |
Enrollment | 286 |
Est. completion date | July 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patient must meet one of the following criteria regarding neurological symptom status and degree of stenosis: - Symptomatic: Stenosis must be greater than or equal to 50% as determined by angiogram and the patient has a history of stroke (minor or non-disabling), TIA and/or amaurosis fugax within 180 days of the procedure. - Asymptomatic: Stenosis must be greater than or equal to 70% as determined by angiogram without any neurological symptoms within the prior 180 days. 2. Target vessel must meet diameter requirements for stent (refer to selected stent IFU for diameter requirements). 3. Patient has a discrete lesion located in the internal carotid artery (ICA) with or without involvement of the contiguous common carotid artery (CCA). 4. Patient is >18 years of age. 5. Patient has no childbearing potential or has a negative pregnancy test within one week prior to the study procedure. 6. Patient (or their legal guardian) understands the nature of the procedure and has provided a signed informed consent using a form that has been reviewed and approved by the Investigational Review Board/Ethics Committee of the respective clinical site prior to the procedure. This will be obtained prior to participation in the study. 7. Patient is willing to comply with the protocol requirements and return to the treatment center for all required clinical evaluations. 8. Patient meets at least one surgical high-risk criteria. Exclusion Criteria: 1. Chronic atrial fibrillation, any episode of paroxysmal atrial fibrillation within the past 6 months, or history of paroxysmal atrial fibrillation requiring chronic anticoagulation. 2. Evolving stroke, severe dementia, intracranial tumor, history of spontaneous intracranial hemorrhage within the past 12 months, recent stroke of sufficient size, hemorrhagic transformation of an ischemic stroke within the past 60 days, history of major stroke with major neurological deficit. 3. Active bleeding diathesis or coagulopathy or will refuse blood transfusion. 4. Had or will have CABG, endovascular stent procedure, valve intervention or vascular surgery within 30 days before or after the intervention. 5. Recently (<60 days prior to procedure) implanted heart valve (either surgically or endovascularly), which is a known source of emboli as confirmed on echocardiogram. 6. Recent GI bleed that would interfere with antiplatelet therapy. 7. Life expectance of < 12 months post procedure. 8. History of intolerance or allergic reaction to any of the study medications or stent materials. 9. Myocardial Infarction within 72 hours prior to the intervention. 10. Has had neurologic illnesses within the past two years characterized by fleeting or fixed neurologic deficit which cannot be distinguished from TIA or stroke. 11. Has Hgb <10 g/dl, platelet count <125,000/µl, uncorrected INR >1.5, bleeding time >1 minute beyond upper limit normal, or heparin-associated thrombocytopenia. 12. Occlusion or (TIMI 0) "string sign" >1cm of the ipsilateral common or internal carotid artery. 13. Has vertebrobasilar insufficiency symptoms only, without clearly identifiable symptoms referable to the study carotid artery. 14. Knowledge of cardiac sources of emboli, Ostium of Common Carotid Artery (CCA) requires revascularization. 15. Presence of extensive or diffuse atherosclerotic disease involving the proximal common carotid artery that would preclude the safe introduction of the study device. 16. Has less than 5cm between the clavicle and bifurcation. 17. Bilateral carotid stenosis if intervention is planned within the 30-day of the index procedure. 18. An intraluminal filling defect that is not associated with an ulcerated target lesion. 19. Abnormal angiographic findings. 20. Previous intervention in the ipsilateral proximal CCA or previous placed intravascular stent in target vessel |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Virgen de la Salud | Toledo | |
United States | Albany Medical Center | Albany | New York |
United States | University of Michigan Medical Center | Ann Arbor | Michigan |
United States | Cardiothoracic & Vascular Surgeons | Austin | Texas |
United States | Johns Hopkins Bayview Medical Center | Baltimore | Maryland |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | University at Buffalo Neurosurgery, Inc | Buffalo | New York |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | University Hospitals Case Medical Center and Case Western Reserve University School of Medicine | Cleveland | Ohio |
United States | Riverside Methodist Hospital | Columbus | Ohio |
United States | Dallas VA Medical Center | Dallas | Texas |
United States | Methodist Medical Center | Dallas | Texas |
United States | McLaren Regional Medical Center | Flint | Michigan |
United States | Greenville Hospital System | Greenville | South Carolina |
United States | Peter Morton UCLA Medical Center | Los Angeles | California |
United States | Columbia University | New York | New York |
United States | Sentara Vascular Specialists | Norfolk | Virginia |
United States | Oklahoma Heart | Oklahoma City | Oklahoma |
United States | Florida Hospital | Orlando | Florida |
United States | Washington University School of Medicine | St. Louis | Missouri |
United States | Jobst Vascular Institute | Toledo | Ohio |
Lead Sponsor | Collaborator |
---|---|
Silk Road Medical |
United States, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Stroke, Myocardial Infarction, and Death | The primary endpoint for overall evaluation of the study is a composite endpoint consisting of the first occurrence of any of the following major adverse events within 30 days. | 30 days post procedure | Yes |
Secondary | Technical Success | The analyses to be conducted on the secondary endpoints are intended to provide additional supportive evidence of the efficacy and safety of the device. | 0 to 30 days | No |
Secondary | Acute Device Success | The analyses to be conducted on the secondary endpoints are intended to provide additional supportive evidence of the efficacy and safety of the device. | 0 to 30 days | No |
Secondary | Procedural Success | The analyses to be conducted on the secondary endpoints are intended to provide additional supportive evidence of the efficacy and safety of the device. | 0 to 30 days | No |
Secondary | Access Site Complications | The analyses to be conducted on the secondary endpoints are intended to provide additional supportive evidence of the efficacy and safety of the device. | 0 to 30 days | No |
Secondary | Contrast Usage | The analyses to be conducted on the secondary endpoints are intended to provide additional supportive evidence of the efficacy and safety of the device. | 0 to 30 days | No |
Secondary | Ipsilateral Stroke | Data on ipsilateral stroke 31-365 days post procedure will be collected to provide additional supportive evidence of the safety of the device. | 31-365 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02124928 -
Morphological and Serological Criteria of Plaque Vulnerability: Risk Assessment for Symptomatic and Asymptomatic Carotid Artery Stenosis
|
N/A | |
Active, not recruiting |
NCT01597453 -
NOR-SYS: The Norwegian Stroke in the Young Study
|
N/A | |
Completed |
NCT00744523 -
Proximal Protection With The Mo.Ma Device During Carotid Stenting
|
N/A | |
Completed |
NCT00231231 -
Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)
|
Phase 3 | |
Completed |
NCT00597974 -
Neurological Outcome With Carotid Artery Stenting
|
N/A | |
Completed |
NCT00587717 -
The Acute Effect of Statins on Inflammatory Markers of Athersclerotic Tissue
|
N/A | |
Completed |
NCT02536378 -
POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE
|
||
Completed |
NCT02126982 -
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence
|
||
Active, not recruiting |
NCT01445613 -
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
|
N/A | |
Terminated |
NCT01414387 -
Effects of Cerebral Protection With Filters vs. Flow Reversal on Cerebral Embolization After Carotid Artery Stenting
|
N/A | |
Completed |
NCT00406055 -
CHOICE: Carotid Stenting For High Surgical-Risk Patients
|
Phase 4 | |
Completed |
NCT00403078 -
SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy
|
||
Terminated |
NCT01968226 -
TRACER RGD-K5 Carotid Plaque Imaging Study
|
Phase 2 | |
Completed |
NCT00402740 -
Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)
|
N/A | |
Completed |
NCT00287508 -
Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study)
|
Phase 4 | |
Completed |
NCT00178672 -
A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery Disease
|
Phase 4 | |
Recruiting |
NCT02850588 -
SVS VQI TransCarotid Revascularization Surveillance Project
|
||
Completed |
NCT02759653 -
Norwegian Carotid Plaque Study
|
||
Withdrawn |
NCT01042912 -
Frequency Analysis of Carotid Artery Disease
|
N/A | |
Completed |
NCT00530504 -
Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study
|
N/A |